Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

156.35
-7.9150-4.82%
Post-market: 156.350.00000.00%19:21 EDT
Volume:680.80K
Turnover:107.84M
Market Cap:8.00B
PE:-42.49
High:163.89
Open:163.89
Low:155.56
Close:164.27
52wk High:191.50
52wk Low:86.99
Shares:51.15M
Float Shares:41.87M
Volume Ratio:1.05
T/O Rate:1.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6800
EPS(LYR):-3.6821
ROE:-252.11%
ROA:-16.81%
PB:90.58
PE(LYR):-42.46

Loading ...

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.

GlobeNewswire
·
Feb 17

Earning Preview: Axsome Therapeutics Q4 revenue is expected to increase by 63.74%, and institutional views are bullish

Earnings Agent
·
Feb 16

Auvelity Priority Review And Revenue Update Could Be A Game Changer For Axsome Therapeutics (AXSM)

Simply Wall St.
·
Feb 06

Axsome Therapeutics Is Maintained at Buy by Jefferies

Dow Jones
·
Feb 03

U.S. RESEARCH ROUNDUP-Adobe, Exxon Mobil, Stellar Bancorp

Reuters
·
Feb 03

Axsome Therapeutics CEO Herriot Tabuteau Reports Disposal of Common Shares

Reuters
·
Feb 03

Axsome Therapeutics AXS-05 Alzheimer's Launch Could Drive Upside, RBC Says

MT Newswires Live
·
Feb 03

Axsome Therapeutics Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Jan 29

Axsome Therapeutics (AXSM) Valuation Check As Phase 3 AXS 14 Fibromyalgia Trial Gets Underway

Simply Wall St.
·
Jan 28

U.S. RESEARCH ROUNDUP- Boeing, Carvana, UnitedHealth

Reuters
·
Jan 28

Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23

GlobeNewswire
·
Jan 27

Axsome Therapeutics Chief Commercial Officer Ari Maizel Reports Disposal of Common Shares

Reuters
·
Jan 24

Axsome Therapeutics (AXSM) Is Up 7.4% After Advancing AXS-14 Into Phase 3 FORWARD Fibromyalgia Trial

Simply Wall St.
·
Jan 23

Axsome Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
Jan 21

Axsome Therapeutics management to meet with Oppenheimer

TIPRANKS
·
Jan 21

RBC Raises Price Target on Axsome Therapeutics to $219 From $212, Keeps Outperform Rating

MT Newswires Live
·
Jan 21

Axsome Therapeutics price target raised to $219 from $212 at RBC Capital

TIPRANKS
·
Jan 21

Axsome Therapeutics Inc : RBC Raises Target Price to $219 From $212

THOMSON REUTERS
·
Jan 21

U.S. RESEARCH ROUNDUP-IBM, KLA, WEX

Reuters
·
Jan 21

Axsome Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 20